Detection of Clopidogrel Resistance Using ADP Induced Aggregometry with Specific Inhibitor PGE1

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33151350" target="_blank" >RIV/61989592:15110/14:33151350 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/14:#0000777

Výsledek na webu

<a href="http://dx.doi.org/10.7754/Clin.Lab.2013.131004" target="_blank" >http://dx.doi.org/10.7754/Clin.Lab.2013.131004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.7754/Clin.Lab.2013.131004" target="_blank" >10.7754/Clin.Lab.2013.131004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Detection of Clopidogrel Resistance Using ADP Induced Aggregometry with Specific Inhibitor PGE1

Popis výsledku v původním jazyce

Backround: Antiaggregation therapy is still the most frequently used approach to prevent thrombotic events in cardiovascular diseases. It has a good clinical effect but increasing evidence shows high residual platelet aggregation activity in a number ofpatients. Laboratory methods only allow us to detect clopidogrel "non-responders" or "low responders". Recent methods are based on monitoring residual platelet aggregation activity (aggregation methods) or detecting the number of free epitopes for binding a specific monoclonal antibody such as vasodilator-stimulated phosphoprotein phosphorylation (VASP). Methods: The aims of our study were comparison light transmission aggregometry (LTA) and multiple electrode platelet aggregometry (MEA) with inductionby ADP in concentrations of 20 mýmol/L with or without prostaglandin E1 (PGE1) for monitoring clopidogrel resistance. Results: In the group of 84 patients with cardiovascular disease (CAD) studied, an impaired individual response to clopi

Název v anglickém jazyce

Detection of Clopidogrel Resistance Using ADP Induced Aggregometry with Specific Inhibitor PGE1

Popis výsledku anglicky

Backround: Antiaggregation therapy is still the most frequently used approach to prevent thrombotic events in cardiovascular diseases. It has a good clinical effect but increasing evidence shows high residual platelet aggregation activity in a number ofpatients. Laboratory methods only allow us to detect clopidogrel "non-responders" or "low responders". Recent methods are based on monitoring residual platelet aggregation activity (aggregation methods) or detecting the number of free epitopes for binding a specific monoclonal antibody such as vasodilator-stimulated phosphoprotein phosphorylation (VASP). Methods: The aims of our study were comparison light transmission aggregometry (LTA) and multiple electrode platelet aggregometry (MEA) with inductionby ADP in concentrations of 20 mýmol/L with or without prostaglandin E1 (PGE1) for monitoring clopidogrel resistance. Results: In the group of 84 patients with cardiovascular disease (CAD) studied, an impaired individual response to clopi

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14394" target="_blank" >NT14394: Vliv exprese tkáňového faktoru na vznik těhotenských komplikací</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Laboratory

ISSN

1433-6510

e-ISSN

—

Svazek periodika

60

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

6

Strana od-do

1475-1480

Kód UT WoS článku

000342857900007

EID výsledku v databázi Scopus

—